Carbon dioxide has been extensively used as a green solvent medium for the crystallization of active pharmaceutical ingredients (APIs) by replacing harmful organic solvents. This work explores the mechanisms underlying a novel recrystallization methodcocrystallization with supercritical solvent (CSS)which enables APIs cocrystallization by suspending powders in pure CO 2 . Six well-known APIs that form cocrystals with saccharin (SAC) were processed by CSS, namely, theophylline (TPL), indomethacin (IND), carbamazepine (CBZ), caffeine (CAF), sulfamethazine (SFZ), and acetylsalicylic acid (ASA). Pure cocrystals were obtained for TPL, IND, and CBZ (with SAC) after 2 h of CSS processing. Convection was revealed to be a determining parameter for successful cocrystallization with high-yield levels. TPL− SAC was selected as a model system to study the cocrystallization kinetics in the gas, supercritical, and liquid phases under different conditions of pressure (8−20 MPa), temperature (30 to 70°C), and convection regimes. The solubility of each substance in CO 2 was measured at the selected working conditions. TPL−SAC showed a cocrystallization rate of 2.9% min −1 , two times higher than that of IND−SAC, due to the higher solubility of TPL in CO 2 . The cocrystallization kinetics was also improved by increasing the CO 2 density, showing that cocrystallization was limited by the dissolution of cocrystal formers. Overall, the CSS process has a potential for scale-up as a novel, simple, solvent-free batch process whenever the cocrystal phase is formed in the CO 2 media.